Previous Close | 0.1800 |
Open | 0.1900 |
Bid | 0.1850 x 0 |
Ask | 0.1900 x 0 |
Day's Range | 0.1850 - 0.1950 |
52 Week Range | 0.1800 - 0.6500 |
Volume | |
Avg. Volume | 78,760 |
Market Cap | 13.133M |
Beta (5Y Monthly) | 0.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0370 |
Earnings Date | Oct 27, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BROSSARD, Quebec, May 10, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the signing of a contract with Farmacias Benavides, a member of Walgreens Boots Alliance in Mexico. “In Farmacias Benavides we are focussed on providing the best health and wellness products for Mexican famil
BROSSARD, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the extension of its contract for the follow-up of Diabetic patients under treatment with drugs included in its therapeutic portfolio. Novo Nordisk’s therapeutic portfolio offers positive benefits by reduc
BROSSARD, Quebec, March 28, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that it has closed a second and final tranche of a non-brokered private placement (“Private Placement”) of 34 additional units (each a “Unit”) at a price of $10,000 per Unit for gross proceeds of $340,000. Combined with the